Skip to main content

Table 1 Preferred medication for PD patients under specific circumstances among doctors of different specialties

From: Current approaches for the management of Parkinson’s disease in Chinese hospitals: a cross-sectional survey

Items

Total (n = 711)a

General physicians (n = 130)

General neurologists (n = 381)

Movement disorders specialists (n = 200)

χ2

P value

Age < 65 years without cognitive impairment

 Levodopa

185 (26.0%)

25 (19.2%)

106 (27.8%)

54 (27.0%)

3.8551

0.1455

 Dopamine agonists

333 (46.8%)

38 (29.2%)

177 (46.5%)

118 (59.0%)

28.0886

< 0.0001

 MAO-B inhibitors

164 (23.1%)

20 (15.4%)

86 (22.6%)

58 (29.0%)

8.3434

0.0154

 Benzhexol

49 (6.9%)

4 (3.1%)

25 (6.6%)

20 (10.0%)

6.0243

0.0492

 Amantadine

101 (14.2%)

13 (10.0%)

55 (14.4%)

33 (16.5%)

2.7671

0.2507

 Levodopa + COMT inhibitors

95 (13.4%)

19 (14.6%)

48 (12.6%)

28 (14.0%)

0.4386

0.8031

Age > 65 years without cognitive impairment

 Levodopa

345 (48.5%)

42 (32.3%)

187 (49.1%)

116 (58.0%)

20.9235

< 0.0001

 Dopamine agonists

180 (25.3%)

22 (16.9%)

99 (26.0%)

59 (29.5%)

6.7851

0.0336

 MAO-B inhibitors

101 (14.2%)

15 (11.5%)

62 (16.3%)

24 (12.0%)

2.8932

0.2354

 Benzhexol

32 (4.5%)

5 (3.9%)

19 (5.0%)

8 (4.0%)

0.4558

0.7962

 Amantadine

69 (9.7%)

8 (6.2%)

44 (11.6%)

17 (8.5%)

3.6800

0.1588

 Levodopa + COMT inhibitors

145 (20.4%)

22 (16.9%)

82 (21.5%)

41 (20.5%)

1.2648

0.5313

Wearing off phenomenon

 Add levodopa dose

127 (17.9%)

15 (11.5%)

67 (17.6%)

45 (22.5%)

6.4953

0.0389

 Adjust protein diet

181 (25.5%)

18 (13.9%)

87 (22.8%)

76 (38.0%)

27.1973

< 0.0001

 Switch from standard levodopa to CR levodopa

260 (36.6%)

30 (23.1%)

140 (36.8%)

90 (45.0%)

16.3361

0.0003

 Add COMT inhibitors or MAO-B inhibitors

326 (45.9%)

48 (36.9%)

163 (42.8%)

115 (57.5%)

16.5500

0.0003

 Recommend surgical treatment

83 (11.7%)

7 (5.4%)

35 (9.2%)

41 (20.5%)

22.3837

< 0.0001

Peak-dose dyskinesia

 Reduce levodopa dose, add its frequency

296 (41.6%)

7 (28.5%)

156 (40.9%)

103 (51.5%)

17.3687

0.0002

 Reduce levodopa dose, add dopamine agonists

319 (44.9%)

33 (25.4%)

168 (44.1%)

118 (59.0%)

36.1891

< 0.0001

 Reduce levodopa dose, add COMT inhibitors

249 (35.0%)

33 (25.4%)

129 (33.9%)

87 (43.5%)

11.8497

0.0027

 Reduce levodopa dose, add MAO-B inhibitors

204 (28.7%)

23 (17.7%)

101 (26.5%)

80 (40.0%)

21.0749

< 0.0001

 Add amantadine

182 (25.6%)

20 (15.4%)

85 (22.3%)

77 (38.5%)

26.7639

< 0.0001

 Switch from CR levodopa to standard levodopa

110 (15.5%)

16 (12.3%)

43 (11.3%)

51 (25.5%)

21.4792

< 0.0001

  1. asix participants supply insufficient data and not included in the present table